National STEM Scholars Announced for 2020 – PR Web

The 2020 Class of National STEM Scholars convened at Gatton Academy at WKU this week

LOUISVILLE, Ky. (PRWEB) August 06, 2020

Nine middle school teachers from eight states have been selected to participate in the prestigious National STEM Scholar Program, a unique professional development program that provides advanced STEM (science, technology, engineering and math) training, national network building, and project support for middle school science teachers nationwide.

Created in partnership between the National Stem Cell Foundation and The Gatton Academy of Mathematics and Science at Western Kentucky University (WKU), the National STEM Scholar Program selects ten teachers each year from a national pool of applicants based solely on the description of a Challenge Project the applicant would implement if funds were not a barrier to execution. Selected projects are chosen for maximum impact in the middle school classrooms where research shows lifelong STEM career decisions are being made. STEM Scholars convene on WKUs campus for a week of advanced STEM training and finalize their Challenge Projects with input from their National STEM Scholar class colleagues. Each Scholar is provided access to a generous stipend for the technology and supplies they need to implement their Challenge Projects at home.

The 2020 National STEM Scholar class will be hosted by The Gatton Academy August 4 - 9 on the campus of WKU in Bowling Green, KY. Selected from approximately 200 applicants across the country, the 2020 National STEM Scholars are:

Dr. Paula Grisanti, CEO of the National Stem Cell Foundation, said, Through our work with researchers and scientists nationwide, we became aware of the widening gap between 21st Century jobs and the U.S. STEM-educated graduates who can fill them. We added education to our mission in 2015 as a way to support the development of a new generation of scientists working to advance technology, build infrastructure and find cures for diseases and conditions that affect us all. Supporting teachers who inspire and motivate middle school students at this critical decision-making age will directly impact how many choose to pursue STEM skills that are essential for 21st Century jobs. By investing in the influential middle school STEM teacher now, we reach thousands of students in classrooms today and far into the future.

Dr. Julia Link Roberts, Executive Director of The Gatton Academy, added, This partnership will accrue benefits for the National STEM Scholars, middle school students in their classrooms, and the middle school science teachers with whom they collaborate. The National STEM Scholar Program is an excellent way for teachers to learn new strategies and new ways to engage students to help them become and stay interested in science and math.

To date, National STEM Scholars represent 49 middle schools in 26 states, from Alaska to New York and Wisconsin to Florida. A significant requirement of selection is the commitment to share lessons learned with colleagues in the Scholars home schools, districts or states, magnifying impact over multiple classrooms and years.

About the National Stem Cell Foundation The National Stem Cell Foundation is a 501(c)3 non-profit organization that funds adult stem cell and regenerative medicine research, connects children with limited resources to clinical trials for rare diseases and underwrites the National STEM Scholar Program for middle school science teachers inspiring the next generation of STEM (science, technology, engineering and math) pioneers nationwide. For more information, visit http://www.nationalstemcellfoundation.org.

About The Gatton Academy Established in 2007, The Gatton Academy of Mathematics and Science is Kentuckys first state-supported, residential program for high school students with interests in advanced math and science careers. One of only 15 such programs in the nation, The Academy has been named to The Washington Posts list of top-performing schools with elite students for eight consecutive years. For more information, visit http://www.wku.edu/academy.

Share article on social media or email:

See the rest here:
National STEM Scholars Announced for 2020 - PR Web

US government considers ethics of aborted tissue research – Catholic News Agency

Washington, D.C. Newsroom, Aug 6, 2020 / 12:00 pm MT (CNA).- A new federal ethics advisory board for fetal tissue research has convened to consider future federally-funded research proposals that involve tissue from aborted babies.

The Human Fetal Tissue Research Ethics Advisory Board of the National Institutes of Health (NIH) met for the first time on July 31, to advise the Health Secretary on the ethics of research proposals involving fetal tissue of aborted babies.

The board was first announced in June of 2019, when the Trump administration decided to halt new research with aborted fetal tissue at NIH facilities, and limited funding of such research conducted outside the NIH.

For the research conducted outside the NIH, or extramural research, the administration announced that an ethics advisory board would be appointed to consider such funding and advise the secretary of Health and Human Services (HHS) on the proposals.

Some researchers have called for the administration to end its moratorium, saying that research with aborted fetal tissue could be vital to developing treatments and a cure for the new coronavirus (SARS-CoV-2).

In February, the HHS announced that it would begin accepting nominations to the board, and during that time period, some researchers at an NIH research laboratory told the Washington Post that the administrations moratorium on fetal tissue research was hindering possible advances in research on treatments for the coronavirus.

Dr. David Prentice, now a member of the NIH Human Fetal Tissue Research Ethics Advisory Board, told CNA in March that the timing of the comments was peculiar as it could have been related to the consideration of appointments to the board.

Several leading coronavirus vaccine candidates are using cell lines from aborted babies, including some funded by the U.S.; other candidates have been determined to be ethically uncontroversial by the pro-life Charlotte Lozier Institute.

One candidate in particularbeing developed by Moderna and the National Institute of Allergy and Infectious Diseasesis not using fetal cell lines directly in production, but is based on research that involved aborted fetal cell lines. As Moderna was not involved in that research, CLI said that the vaccine candidate is ethically uncontroversial.

The NIH ethics board members are appointed for a duration that lasts as long as the board is convened; the boards charter says that [t]he estimated annual person-years of staff support required is 0.7. Appointments to the board are made by the HHS secretary.

Heading the advisory board is Paige Cunningham, interim president of Taylor University, an evangelical Christian university in Indiana.

Several Catholic bioethicists are on the board, including Fr. Tadeusz Pacholczyk, director of education at the National Catholic Bioethics Center. The co-chair of the Catholic Medical Association (CMA) ethics committee, Greg Burke, is a member, along with CMA member Dr. Ashley Fernandes of the Ohio State University medical school.

The pro-life Charlotte Lozier Institute (CLI) is also represented on the board, with CLI vice president Dr. David Prentice and associate scholars Ingrid Skop and Maureen Condic as members.

Some board members, such as Dr. Lawrence Goldstein of the University of California San Diego, support fetal tissue research; he called cell lines from fetal tissue critical in vaccine development, along with stem cell research and the use of humanized mice to develop immune cell-forming tissues.

Two members testified in 2016 before the House select investigative panel of the Energy and Commerce Committee, in a hearing on bioethics and fetal tissue.

Cunningham said at the hearing that [t]he fetus is a human subject entitled to the protections that both traditional and modern codes of medical ethics provide to human subjects.

Kevin Donovan, MD, director of the Pellegrino Center for Clinical Bioethics at Georgetown University Medical Center, also testified, noting the current moral ambiguity in the nations discourse on abortion.

We have decided that we can legally abort the same fetus that might otherwise be a candidate for fetal surgery, even using the same indications as justification for acts that are diametrically opposed, he said. We call it the fetus if it is to be aborted and its tissues and organs transferred to a scientific lab. We call it a baby, even at the same stage of gestation, when someone plans to keep it and bring it into their home.

If we cannot act with moral certainty regarding the appropriate respect and dignity of the fetus, we cannot morally justify its destruction, he said.

During the public portion of the July 31 meeting, board members were introduced and then heard from several researchers who were either in support of or in opposition to research using fetal tissue from elective abortions.

The 2008 Vatican document Dignitatis Personae addressed the topic of aborted fetal tissue research, saying that there is a duty to refuse to use such biological material even when there is no close connection between the researcher and the actions of those who performed the artificial fertilization or the abortion, or when there was no prior agreement with the centers in which the artificial fertilization took place.

This duty springs from the necessity to remove oneself, within the area of ones own research, from a gravely unjust legal situation and to affirm with clarity the value of human life, the Congregation for the Doctrine of the Faith document stated.

Read this article:
US government considers ethics of aborted tissue research - Catholic News Agency

Cell Viability Assays Market by Production Analysis, Current Trends 2024 Analysis of Regions with Top vendors, Market Dynamics, Types, Applications,…

Market Challenge: Threats in major regions

Cell Viability Assays Market Report Highlights:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/15398351

Cell Viability Assays Market Segmentation Covers:

Product: o Consumables

o Instruments

Regional Segmentation:

The objective of Studies:

Purchase this Report (Price 2500 USD for single-user license) https://www.industryresearch.co/purchase/15398351

Some Points from Cell Viability Assays Market Report TOC:

PART01:EXECUTIVESUMMARY

PART02:SCOPEOFTHEREPORT

PART03:MARKETLANDSCAPE

PART04:MARKETSIZING

PART05:FIVEFORCESANALYSIS

PART06:MARKETSEGMENTATIONBYTECHNOLOGY

PART07:MARKETSEGMENTATIONBYFURNACETYPE

PART08:CUSTOMERLANDSCAPE

PART09:GEOGRAPHICLANDSCAPE

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

For Detailed TOC Click Here

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Nanomaterials in Cosmetic and Personal Care Market Growth Size, Share 2020 | Industry Analysis with COVID-19 Impact, Company Overview, Key Countries with Future Prospect to 2026

Needle-Free IV Connectors Market Size Outlook 2020 to 2025: Market Trends, Segmentation, Growth Rate and Competitive Landscape with COVID-19 Outbreak

Automated Material Handling and Storage System Market 2020| Worldwide Overview by Industry Size, Market Share, Future Trends, Growth Factors and Leading Players Research Report Analysis till 2025

Non-dairy Creamer Fats Market Growth Trends with Key Players 2020 Size by Regions, Global Industry Share, Sales Revenue and Opportunities till 2026 with COVID-19 Impact

Petroleum Jellies Market 2020 Global Industry Size Estimation, Research Update, Future Scope, Revenue, Pricing Trends, Growth Opportunity, Regional Outlook and Forecast to 2025

Toy Balloon Market Size | Share Forecast 2020 to 2026: Competition Analysis, Industry Growth by New Innovations, Top Players Analysis with COVID-19 Impact

Here is the original post:
Cell Viability Assays Market by Production Analysis, Current Trends 2024 Analysis of Regions with Top vendors, Market Dynamics, Types, Applications,...

Stem Cell Assay Market Study for 2020 to 2027 providing information on Key Players, Growth Drivers and Industry challenges – Bulletin Line

COVID-19 can influence the global economy in three ways: by directly influencing production and demand, by creating supply chain and market disruptions, and by having a financial impact on businesses and financial markets. The eruption of COVID-19 has implications for many aspects such as flight cancellations. Travel bans and quarantines; Restaurants closed; all Indoor Events restricted; over forty countries declared a state of emergency; massive supply chain slowdown; stock market volatility; falling business confidence, growing panic in the population and uncertainty about the future.

This report examines the global Stem Cell Assay Market and analyses and examines the Stem Cell Assay Market development status and forecast in the US, EU, Japan, China, India and Southeast Asia. This report focuses on the highest players in the global Stem Cell Assay Market .

Ask For Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24266&utm_source=BLN&utm_medium=001

The scope of the report covers all major system technologies currently being implemented in the global Stem Cell Assay Market industry. Market values are supported the Top User (public and private) supports the production of Stem Cell Assay Market systems. Stem Cell Assay Market manufacturers place orders as soon as they receive work orders from Stem Cell Assay Market operators. Therefore, market figures are derived from the perspective of the top users taking into account their orders (Stem Cell Assay Market operator) for the Stem Cell Assay Market .

The Stem Cell Assay Market was created on the basis of an in-depth market analysis with contributions from industry experts. The report covers the growth prospects in the coming years and the discussion of the main providers.

Market drivers

Increasing deforestation due to increasing demand for increasing raw materials

For a full, detailed list, see our report

Market Challenge

Risks associated with the use of Stem Cell Assay Market

For a full, detailed list, see our report

Market Trend

Increasing consumer preference for Stem Cell Assay Market For a full, detailed list, see our report

The global market research report of Stem Cell Assay Market industry 2020 is distributed over several pages and contains exclusive Statistics, data, information, Stem Cell Assay Market trends and details of the competitive landscape in this niche sector.

To understand how the effects of COVID-19 are addressed in this report. A sample copy of the report is available at https://www.verifiedmarketresearch.com/product/Stem-Cell-Assay-Market/?utm_source=BLN&utm_medium=001

The report also focuses on the worlds leading industry players in the global Stem Cell Assay Market , providing information such as company profiles, product images and specifications, capacity, production, price, cost, revenue and contacting information. In addition, upstream raw materials and equipment as well as downstream demand analyses are managed. The global Stem Cell Assay Market development trends and market channels are analyzed. Finally, the feasibility of the latest investment projects is evaluated and general research results are offered. With tables and figures to help analyze the global Stem Cell Assay Market , this study provides important statistics on the state of the industry and can be a valuable guide and guidance for companies and individuals who are curious about the market.

Verified Market Researchis a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Mr. Edwyne Fernandes

US: +1 (650)-781-4080 UK: +44 (203)-411-9686 APAC: +91 (902)-863-5784 US Toll-Free: +1 (800)-7821768

Email:[emailprotected]

Read more here:
Stem Cell Assay Market Study for 2020 to 2027 providing information on Key Players, Growth Drivers and Industry challenges - Bulletin Line

Allogeneic Stem Cells Market 2020-2024: Business Overview, Industry Size and Share, Opportunities, Impact of Drivers, Key Venders, Types, Applications…

New product approvals The new product approvals and special drug designations are anticipated to boost the growth of the market. Based on the application, the allogeneic stem cells market has been segmented into regenerative therapy and drug discovery and development. Manufacturers are increasingly emphasizing innovations and improvisation in the development of regenerative therapies. Many of the regenerative therapeutic candidates have obtained approval for clinical trials in the US, Europe, and APAC due to the efficacy of allogeneic stem cell therapeutics. This is encouraging market players to launch new product lines to stimulate the overall product demand for stem or regenerative therapy using allogeneic stem cell therapeutics and provide better options for their customers. Thus, new product approvals will lead to the expansion of the global allogeneic stem cells market at a CAGR of over 12% during the forecast period.

Special drug designations Research in the field of stem cell focuses mainly on developing new treatments for deadly diseases, which have negligible treatment using traditional treatment options. Thus, therapeutic candidates, which are currently under development, have been awarded special drug designations by regulatory bodies considering their proven efficacy. Many drugs received designations such as the breakthrough drug designation and the orphan drug designation from regulatory bodies such as the US FDA and the EMA. Drug designations enhance the research and enable drugs to reach the market and provides strong incentives, which in turn, encourages vendors to expedite R&D on novel therapies such as allogeneic stem cell therapy. This development is expected to have a positive impact on the overall market growth.

Allogeneic Stem Cells Market Report Highlights:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/15047388

Allogeneic Stem Cells Market Segmentation Covers:

By Type:

Regional Segmentation:

The objective of Studies:

Purchase this Report (Price 2500 USD for single-user license) https://www.industryresearch.co/purchase/15047388

Some Points from Allogeneic Stem Cells Market Report TOC:

PART01:EXECUTIVESUMMARY

PART02:SCOPEOFTHEREPORT

PART03:MARKETLANDSCAPE

PART04:MARKETSIZING

PART05:FIVEFORCESANALYSIS

PART06:MARKETSEGMENTATIONBYTECHNOLOGY

PART07:MARKETSEGMENTATIONBYFURNACETYPE

PART08:CUSTOMERLANDSCAPE

PART09:GEOGRAPHICLANDSCAPE

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

For Detailed TOC Click Here

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Pre-Owned Medical Devices Market Size Outlook 2020 to 2025: Market Trends, Segmentation, Growth Rate and Competitive Landscape with COVID-19 Outbreak

Microsclerotherapy Treatment Market 2020 Global Industry Revenue, Key Strategies, Business Growth Rate by Size, and Top Key Players with COVID-19 Outbreak Forecast to 2025

Weighing Indicators Market Size by Top Key Players 2020 Global Growth Rate by Share, Industry Segment, Future Prospect, Key Finding and Market Dynamics Forecast to 2026

Polyhydric Alcohol Phosphate Ester (PAPE) Market Growth Size, Share 2020 | Industry Analysis with COVID-19 Impact, Company Overview, Key Countries with Future Prospect to 2026

Self-contained Breathing Apparatus (SCBA) Market Share and Size Analysis 2020 by Regional Demand Status, Future Growth Rate, Manufacturers, Trends by Market Dynamics and Development Scope till 2026

Warehouse Management Systems Market 2020 Trends, Manufacturing Size, Growth Analysis by Share, Top Regions, Driving Factors of Manufacturers, Types and Applications Forecast to 2023

Read this article:
Allogeneic Stem Cells Market 2020-2024: Business Overview, Industry Size and Share, Opportunities, Impact of Drivers, Key Venders, Types, Applications...

Cancer Stem Cell Therapeutics Market Emerging Trends, Business Opportunities, Segmentation, Production Values, Supply-Demand, Brand Shares and…

Reports and Data has recently added a new research study on the Global Cancer Stem Cell Therapeutics Market to its ever-expanding database. The report is equipped with detailed information about the product types, applications, regions, and key players operating in the market. The report provides a comprehensive analysis of the emerging trends, key challenges, growth potential, drivers, competitive landscape, and industrial chain analysis of the Global Cancer Stem Cell Therapeutics industry.

The latest report is furnished with the impact analysis of the current COVID-19 pandemic on the market. The pandemic has drastically changed the dynamics of the market and has affected every aspect of life globally. The rapidly changing dynamics of the market and current and future growth potential of the market are covered in the report. The report offers crucial information about the initial and future assessment of the impact of the COVID-19 crisis on the overall market.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1414

The report covers an exhaustive analysis of manufacturing processes, development policies, plans, product portfolio, and cost analysis. The data is represented in the form of tables, charts, graphs, diagrams, and figures.

Furthermore, the report includes an in-depth analysis of the competitive landscape. The segment offers a comprehensive overview of the company profiles along with the product profiles, production capacities, products/services, pricing analysis, profit margins, and manufacturing process developments. The report also covers strategic business measures undertaken by the companies to gain substantial market share. The report provides insightful information about recent mergers and acquisitions, product launches, collaborations, joint ventures, partnerships, agreements, and government deals.

The report provides an in-depth analysis of the competitive landscape and covers profiles of key players, along with their product portfolios and business strategies.

Key players of the market mentioned in the report are:

Merck KGA, LONZA Group AG, Novartis, Osiris Therapeutics, Pfizer, Pfizer, Stemline Therapeutics Inc., STEMCELL Technologies, and Thermo Fischer Scientific Inc.

The report analyzes various product types and applications, along with manufacturing and process analysis and cost analysis. The data is further validated via extensive primary and secondary research verified by industry experts and professionals of the profiled companies.

Treatment Type: (Revenue, USD Million; 20162026)

Disease Type: (Revenue, USD Million; 20162026)

Application: (Revenue, USD Million; 20162026)

End Use: (Revenue, USD Million; 20162026)

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1414

Highlights of the Cancer Stem Cell Therapeutics Report:

The report covers historical revenue and sales volume, and the data is validated to provide a forecast market estimation of the market size and sales numbers for key regions along with types and end-user applications. Moreover, the report also includes macroeconomic factors and regulatory policies pertaining to the Cancer Stem Cell Therapeutics industry for evaluation and predictive analysis.

Additionally, the report provides beneficial data about distribution, production, consumption patterns, export/import, and demand and supply ratio. The report covers the latest trends, product portfolio, demographics, regional segmentation, and regulatory framework of the Cancer Stem Cell Therapeutics industry.

Based on the geographical spread, the Cancer Stem Cell Therapeutics industry is segmented into North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa.

Request customization of the report @ https://www.reportsanddata.com/request-customization-form/1414

Highlights of the TOC of the Cancer Stem Cell Therapeutics Market Report:

Global Cancer Stem Cell Therapeutics Market Overview

Global Cancer Stem Cell Therapeutics Market Size and Share by Types

Global Cancer Stem Cell Therapeutics Market Size and Share by Applications

Global Cancer Stem Cell Therapeutics Market Sales and Growth Rate

Global Cancer Stem Cell Therapeutics Market Competitive Landscape

Global Cancer Stem Cell Therapeutics Market Regional Analysis

Global Cancer Stem Cell Therapeutics Market Forecast Estimation (2020-2027)

Global Cancer Stem Cell Therapeutics Market Trends, Drivers, Challenges, Risks, and Opportunities

Global Cancer Stem Cell Therapeutics Market Revenue, Price, and Gross Margin for Each Segment

Global Cancer Stem Cell Therapeutics Market Industrial Chain Analysis

Read more about the TOC in the full report.

To get the Report Description and TOC, visit @ https://www.reportsanddata.com/report-detail/cancer-stem-cell-therapeutics-market

Thank you for reading our report. Customization of this report is available on chapter wise section or region wise. Kindly get in touch with us to know more about the report, and our team will provide the report suited to your needs.

See the original post:
Cancer Stem Cell Therapeutics Market Emerging Trends, Business Opportunities, Segmentation, Production Values, Supply-Demand, Brand Shares and...

IMAC Holdings Receives FDA Authorization to Initiate Clinical Study of Its Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for the Treatment…

August 05, 2020 11:58 ET | Source: IMAC Holdings, Inc.

BRENTWOOD, Tenn., Aug. 05, 2020 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (the Company or IMAC), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced the United States Food and Drug Administration (the FDA) approved its investigational new drug application, which IMAC submitted in May 2020, for the use of umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia, or the gradual loss and slowing down of spontaneous body movement, due to Parkinsons disease.

The Company will now initiate enrollment of 15 patients for its Phase 1 trial to evaluate the safety and tolerability of the stem cell product acquired from technology developed by a major research university to treat patients with Bradykinesia due to Parkinsons utilizing intravenous administration of Whartons jelly-derived mesenchymal stem cells. The Company believes that the causes of bradykinesia may be related to an inflammatory response in the body. The Companys new study is designed to confirm this belief and support the Companys long-term strategy for the use of regenerative medicine in combination with physical rehabilitation to reduce the effect of movement-restricting diseases.

Our regenerative rehabilitation centers have long focused on the importance of finding and applying non-opioid, non-surgical solutions to physical ailments in orthopedics. In 2017, our neurosurgeon researched opportunities to apply stem cells to treating Parkinsons, and we put a team together to design a treatment for our neurological patients that simply could not achieve maximum benefit from physical therapy alone, commented Jeffrey Ervin, IMACs Chief Executive Officer. Having received approval to proceed with our study, IMAC is extremely optimistic regarding the potential of this stem cell technology. This has the potential to not only expand proprietary service options for neurological patients, but also advance the way physically debilitating inflammatory conditions are managed as a whole. We would like to thank the FDA for the collaborative process and the partners who helped us achieve this milestone, including patient advocate, Doug Oliver and his team at Regenerative Outcomes.

The Phase 1 trial will consist of three treatment protocols: five patients with bradykinesia due to Parkinsons will receive a low dose intravenous infusion of stem cells, five patients will receive a medium dose intravenous infusion of stem cells and five patients will receive a high dose intravenous infusion of stem cells. The Phase 1 trial will be conducted over 12 months to determine the incidence and extent of adverse events, although the Company will also investigate the efficacy of its stem cell treatment. More information on the clinical trial, including patient criteria, can be found on clinicaltrials.gov.

IMAC will enroll participants from its existing clinics in Illinois, Tennessee, Kentucky and Missouri in its Phase 1 trial. Prospective enrollees may email fdatrial@imacregeneration.com to be considered for the trial. IMACs medical doctors and physical therapists have been trained to administer the treatment and manage the therapy for the clinical trial, which is anticipated to begin in 30 days.

About IMAC Holdings, Inc.

IMAC Holdings was created in March 2015 to expand on the footprint of the original IMAC Regeneration Center, which opened in Kentucky in August 2000. IMAC Regeneration Centers combine life science advancements with traditional medical care for movement restricting diseases and conditions. IMAC owns or manages 16 outpatient clinics that provide regenerative, orthopedic and minimally invasive procedures and therapies. It has partnered with several active and former professional athletes, opening six Ozzie Smith IMAC Regeneration Centers, two David Price IMAC Regeneration Centers, as well as Mike Ditka IMAC Regeneration Centers and a Tony Delk IMAC Regeneration Center. IMACs outpatient medical clinics emphasize its focus around treating sports and orthopedic injuries and movement-restricting diseases without surgery or opioids. More information about IMAC Holdings, Inc. is available at http://www.imacregeneration.com.

# # #

Safe Harbor Statement

This press release contains forward-looking statements. These forward-looking statements, and terms such as anticipate, expect, believe, may, will, should or other comparable terms, are based largely on IMAC's expectations and are subject to a number of risks and uncertainties, certain of which are beyond IMAC's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the skills and experience necessary to meet customers requirements, and its ability to protect its intellectual property. IMAC encourages you to review other factors that may affect its future results in its registration statement and in its other filings with the Securities and Exchange Commission. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will in fact occur.

IMAC Press Contact: Laura Fristoe lfristoe@imacrc.com

IMAC Investor Contact: Bret Shapiro (516) 222-2560 brets@coreir.com

Source: IMAC Holdings, Inc.

Continue reading here:
IMAC Holdings Receives FDA Authorization to Initiate Clinical Study of Its Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for the Treatment...

Hematopoietic Stem Cell Transplantation (HSCT) Market 2020: Regen Biopharma Inc, China Cord Blood Corp, CBR Systems Inc, Escape Therapeutics Inc,…

The latest report published by Regal Intelligence on Hematopoietic Stem Cell Transplantation (HSCT) market provides crucial market insights along with detailed segmentation analysis. The report examines key driving factors that are expected to drive the growth of the market.

Global Hematopoietic Stem Cell Transplantation (HSCT) Market Research Report gives knowledgeable information on various market situations, for example, potential development factors, factors controlling the development, market opportunities and dangers to the worldwide market. Also, the report broadly centers around competitive analysis of Hematopoietic Stem Cell Transplantation (HSCT) Market. The competitive analysis segment incorporates key manufacturers, fresh players, providers, market strategies, potential chances, operation landscape and analysis of the trends of the Hematopoietic Stem Cell Transplantation (HSCT) market. The market results are centered around current market scenario. To gauge and predict the degree of competition in this market. This report will likewise support all the manufacturers and speculators to have a superior comprehension of the investments to know where the market is heading.

Get a Sample Copy of this Report @ https://www.regalintelligence.com/request-sample/98196

Leading players of Hematopoietic Stem Cell Transplantation (HSCT) including: Regen Biopharma Inc, China Cord Blood Corp, CBR Systems Inc, Escape Therapeutics Inc, Cryo-Save AG, Lonza Group Ltd, Pluristem Therapeutics Inc, ViaCord Inc

For Product type segment the report listed main product type:

Allogeneic Autologous

For Application segment the report listed main types:

Peripheral Blood Stem Cells Transplant (PBSCT) Bone Marrow Transplant (BMT) Cord Blood Transplant (CBT)

Key Highlights of the Hematopoietic Stem Cell Transplantation (HSCT) Market

Key Strategies adopted by major players Global driving factors of the market Developed and emerging markets Comprehensive description of the international players Market dynamic factors affecting the global market Evaluation of niche business areas Driving and restraining factors of the market growth Market share analysis

Moreover, the report briefly studies the performance of both historical records along with the recent trends. It includes a complete analysis of different attributes such as manufacturing base, type, and size. This report evaluates the market segmentation along with the competitive landscape at global as well as regional level. The report also discusses about the rising need for Hematopoietic Stem Cell Transplantation (HSCT) market.

Reasons for Buying this Report

Feel Free to Consult our Analyst Before Purchasing the Report @ https://www.regalintelligence.com/enquiry/98196

Report on Global Hematopoietic Stem Cell Transplantation (HSCT) Market 2020 comprises of 10 Sections in Table as follows:

The Hematopoietic Stem Cell Transplantation (HSCT)-market report reads pin-direct analysis for changing serious dynamics with reference towards changing elements that drives or limits market development. The report is comprehensively visualized to forecast the market point of view and opportunities where it has an extension to develop in future. Basically, the report segregates the ability of market in the present and the future possibilities from various edges in detail.

About Us: We, Regal Intelligence, aim to change the dynamics of market research backed by quality data. Our analysts validate data with exclusive qualitative and analytics driven intelligence. We meticulously plan our research process and execute in order to explore the potential market for getting insightful details. Our prime focus is to provide reliable data based on public surveys using data analytics techniques. If you have come here, you might be interested in highly reliable data driven market insights for your product/service,reach us here 24/7.

We are always happy to assist you on your queries: [emailprotected]Phone No:+1 231 930 2779 (U.S.) +44 141 628 8787 (UK) Regal Intelligence: http://www.regalintelligence.com

Read the original here:
Hematopoietic Stem Cell Transplantation (HSCT) Market 2020: Regen Biopharma Inc, China Cord Blood Corp, CBR Systems Inc, Escape Therapeutics Inc,...

BioTech Life Sciences Initiates New Study of Anti-Aging Formulas in Helping COVID-19 ‘Long-Haulers’ and Those Suffering With Chronic Fatigue Syndrome…

LONDON, Aug. 5, 2020 /PRNewswire/ --BioTech Life Sciences (BioTech https://btl.science) recently announced it was studying the effects of its proprietary formulas on long-term patient symptoms related to COVID-19 Post-Viral Fatigue (long-haulers) and chronic fatigue syndrome (C.F.S.).

The findings will be a part of a larger research study undertaken by the company, and is currently calling for voluntary participants; especially those who suffer from myalgic encephalomyelitis (M.E.), chronic fatigue syndrome, or Post-Viral Fatigue.

BioTech specializes in anti-aging, stem cell production and neuroscience, and has discovered a clear link between COVID-19 long-haulers, C.F.S., and the therapeutic benefits of certain anti-aging compounds.

The Link Between Post-Viral Fatigue and M.E./C.F.S.

According to the Cleveland Clinic and a recent Atlantic article, patients who survive COVID-19 typically recover in roughly two weeks' time. But there are a growing number of patients as many as 20% who inexplicably suffer with the disease for months, with longer lasting complications. These so called long-haulers report symptoms including fevers, chest pain, shortness of breath and debilitating fatigue.

Researchers are not sure why these patients experience COVID-19 for prolonged periods. Theories range from reinfection, to viral reactivation (similar to herpes), to a whole new syndrome initiated by COVID-19 infection. Patients are increasingly describing symptoms that are similar to the conditions of M.E./C.F.S, but more research is needed.

"What we're all seeing is a large, unexplained increase in people who are not making a full recovery from COVID-19," said Nicole Wong, lead researcher for BioTech. "We have already found several links between these long-haulers and M.E./C.F.S. patients. First, both groups seem to suffer from their cellular batteries mitochondria not producing enough energy. SARS-CoV-2 hijacks and destroys mitochondria, essentially eating their contents to replicate, and inflammatory cytokines such as TNF-alpha and IL-6, also reduce ATP-energy production."

Coronavirus blocking ACE2 causes a massive increase in free radicals and oxidative stress. These free radicals damage the lining of the blood vessels and can lead to blood clotting, thrombosis and the infamous cytokine-storm. It also increases enzyme CD38, which is known to greatly decrease ATP-energy production in multiple ways.

BioTech Life Sciences: Upcoming Clinical Trials Offer Hope

"While developing our anti-aging formulas, participants reported a profound increase in energy," said Romy Jardine, BioTech Chief Scientific Officer. "We discovered this was down to an increase in mitochondrial energy production, and this would likely help alleviate the crippling fatigue that many M.E./C.F.S. and long-haulers suffer with.

"The research is incredibly complex and will take time, as it involves the central nervous system, inflammatory cytokines, and multiple elements of the immune system. But now that we understand how to coax mitochondria into producing more energy, we're hopeful that this can be applied as a therapy for long-haulers and C.F.S. fatigue. Our upcoming clinical trials will begin to shed more light on those possibilities."

To learn more, or to take part in the upcoming BioTech clinical trial for C.F.S. or Post-Viral Fatigue sufferers, please visit: https://btlscience.typeform.com/to/XnVlAbmJ.

About BioTech Life Sciences

BioTech Life Sciences is a London-based company dedicated to research and development in anti-aging. Bringing the latest advances in stem cell production, DNA repair, epigenetics and neuroscience, BioTech optimizes health and promotes longevity. Currently involved in multiple research projects, BioTech is focusing on mitochondrial energy production (incl mitochondrial Biogenesis). BioTech is also studying Post-Viral Fatigue related to COVID-19, C.F.S. and M.E. Learn more about the latest BioTech developments at: http://www.BTL.science.

Disclaimer: These statements have not been evaluated by the FDA, MHRA, EMEA or any other regulatory or medical body. These products are not intended to diagnose, treat, cure, or prevent any disease. All information presented here is not a substitute for information from licensed healthcare practitioners. If you are on medication consult your healthcare professional about potential interactions or other complications.

Media Contact:

Freddy Keefe +44.7429.330606 [emailprotected]

SOURCE BioTech Life Sciences

http://btl.science

Continued here:
BioTech Life Sciences Initiates New Study of Anti-Aging Formulas in Helping COVID-19 'Long-Haulers' and Those Suffering With Chronic Fatigue Syndrome...

COVID-19 Industry Impact On Autologous Stem Cell and Non-Stem Cell Based Therapies Market Revenue Develop Rapidly By 2019 2027 | Fibrocell Science,…

The report offers a systematic presentation of the existing trends, growth opportunities, market dynamics that are expected to shape the growth of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market. The various research methods and tools were involved in the market analysis, to uncover crucial information about the market such as current & future trends, opportunities, business strategies and more, which in turn will aid the business decision-makers to make the right decision in future.

Whats keeping Caladrius Biosciences, Vericel Corporation, Fibrocell Science, Inc., Genzyme Corporation, BrainStorm Cell Therapeutics, Regeneus Ltd., and Dendreon Corporation. Ahead in the Market? Benchmark yourself with the strategic moves and findings recently released by CMI

Request a Sample Copy:https://www.coherentmarketinsights.com/insight/request-sample/523

List of Companies Mentioned:Caladrius Biosciences, Vericel Corporation, Fibrocell Science, Inc., Genzyme Corporation, BrainStorm Cell Therapeutics, Regeneus Ltd., and Dendreon Corporation.

1) Does Study provides Latest Impact on Market due to COVID & Slowdown?

Yes study have considered a chapter on Impact Analysis and this 2020 Edition of the report provides detailed analysis and its impact on growth trends and market sizing to better understand current scenario.

2) How companies are selected or profiled in the report?

List of some players that are profiled in the the report includes Caladrius Biosciences, Vericel Corporation, Fibrocell Science, Inc., Genzyme Corporation, BrainStorm Cell Therapeutics, Regeneus Ltd., and Dendreon Corporation.. list is sorted to come up with a sample size of atleast 50 to 100 companies having greater topline value to get their segment revenue for market estimation.

** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

3) Is it possible to narrow down business segments by Application of this study?

Yes, depending upon the data availability and feasibility check by our Research Analyst, further breakdown in business segments by end use application in relation to type can be provided (If applicable) by Revenue Size or Volume*.

4) What is the base year of the study? What time frame is covered in the report?

Furthermore, the years considered for the study are as follows:

Historical year 2014 2018

Base year 2018

Forecast period** 2019 to 2027 [** unless otherwise stated]

**Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, detailed analysis of competitive landscape and product services of key players.

Detailed Segmentation:

On the basis of application, the global autologous stem cell and non-stem cell based therapies market is classified into:Neurodegenerative diseasesCardiovascular diseasesCancer and autoimmune diseasesSkin transplantationInfectious disease

Regions included:

o North America (United States, Canada, and Mexico)

o Europe (Germany, France, UK, Russia, and Italy)

o Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

o South America (Brazil, Argentina, Colombia)

o Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market What to expect from this report:

Focused Study on Niche Strategy and Market Development & penetration Scenario

Analysis of M&As, Partnership & JVs in Global Autologous Stem Cell and Non-Stem Cell Based Therapies Industry in United States & Other Emerging Geographies

Top 10 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Companies in Global Market Share Analysis: Leaders and Laggards in 2017, 2019

Gain strategic insights on competitor information to formulate effective R&D moves

Identify emerging players and create effective counter-strategies to outpace competitive edge

Identify important and diverse product types/services offering carried by major players for market development

And many more .

TABLE OF CONTENTS

Report Overview:It includes the Autologous Stem Cell and Non-Stem Cell Based Therapies market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary:This section of the report gives information about Autologous Stem Cell and Non-Stem Cell Based Therapies market trends and shares, market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players:Here, key players of the Autologous Stem Cell and Non-Stem Cell Based Therapies market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study:All of the regions and countries analyzed in the Autologous Stem Cell and Non-Stem Cell Based Therapies market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

Download PDF Brochure @https://www.coherentmarketinsights.com/insight/request-pdf/523

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods.

Mr Raj Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone +1-206-701-6702 [emailprotected]

See more here:
COVID-19 Industry Impact On Autologous Stem Cell and Non-Stem Cell Based Therapies Market Revenue Develop Rapidly By 2019 2027 | Fibrocell Science,...